ORCHARD PARK, N.Y. — Sunday brought one of the Jets' most embarrassing losses in recent memory, as they fell behind by 40 in a 40-14 loss to the Bills. The frustration was unmistakable in the locker room, with several players unable to hide their exasperation after falling to 4-12 on the season. But in terms of concrete results, the penultimate game of this lost season provided a major win in the chase for a top pick in the 2025 NFL Draft. According to Tankathon.com, the Jets now sit at No. 6 in the 2025 NFL Draft order, jumping up two spots from No. 8 at the beginning of Week 17. That’s likely where they’ll stay for this week, although there’s a chance they could move up to No. 5 if Cleveland comes back to beat the Dolphins in the fourth quarter, and a chance they move to No. 7 if Carolina’s strength of schedule slips below the Jets'. As of early Sunday evening the Jets are one of five teams with four wins this season, benefiting especially from the Raiders' second straight win (to reach four wins) as they moved ahead of Las Vegas in the draft order. BUY NFL TICKETS: STUBHUB , VIVID SEATS , TICKETSMARTER , TICKETMASTER The Jaguars, who beat the Titans on Sunday to get to 4-12, are the only four-win team ahead of the Jets because of strength of schedule — Jacksonville’s .472 mark is worse than the Jets .496. At .498, Carolina could pull ahead of the Jets depending on how the final games of Week 17 play out. But the other four-win teams — Las Vegas (.546) and Chicago (.553) likely have too great a strength-of-schedule difference with the Jets to pass them in the order if they finish the season with the same record. With Cleveland (.537) and the Giants (.551) both with a significantly higher strength of schedule than the Jets, the Jets would likely pass either if they lose to the Dolphins and either picks up another win. MORE JETS COVERAGE Jets' Aaron Rodgers made wrong kind of history in lopsided loss to Bills Jets' Aaron Rodgers replaced by Tyrod Taylor late in humiliating loss to Bills New York Jets vs. Buffalo Bills LIVE STREAM (12/29/24): Watch NFL Week 17 online | Time, TV, Channel What channel is the New York Jets game today (12/29/24)? FREE LIVE STREAM, Time, TV, Channel for NFL Week 17 vs. Buffalo Bills Jets' Davante Adams still has plenty to play for vs. Bills, despite injury Thank you for relying on us to provide the journalism you can trust. Please consider supporting us with a subscription. Andy Vasquez may be reached at avasquez@njadvancemedia.com .
The Swans stunned Pride Park into silence with less than two minutes on the clock when Zan Vipotnik sent a bullet past Jacob Widell Zetterstrom before Ronald slotted home his first of the season in the 14th minute. Cyrus Christie brought Tom Barkhuizen down inside the box and Nathaniel Mendez-Laing dispatched the resulting penalty to cut the deficit in half and, despite piling on the pressure, Derby succumbed to a second home defeat of the season. Williams told a press conference: “We started the game very well, we were good up until we scored the second goal then we lost the grip on the game and I thought Derby were the better team. “The next thing for us we have to be able to maintain that level throughout the game and we weren’t able to do that to be quite honest today. “They made it difficult, reacted very well after the second goal and didn’t go under, far from it.” Swansea leapfrogged their opponents into the top half of the table with their sixth win of the season and took three points back to south Wales following two last-minute defeats by Burnley and Leeds heading into the match. Williams added: “We’ve recently conceded late goals but they’re a very resilient group and we saw it out in the end. “We’ve dominated games a lot but probably failed to score when we’ve been that dominant and tonight we managed to score the goals when we were dominant. “We scored the goals at the right time today.” Derby had been unbeaten in their last three matches coming into this one but Paul Warne put defeat down to a poor start. He said: “We conceded two and didn’t get close enough, weren’t aggressive enough, not enough body contact and looked soft, that’s my fault. “Maybe I didn’t message it properly. Sometimes it doesn’t come down to shape and tactics but I thought that was what the difference was. “Credit Swansea for the win but after the 25 mins it looked like we would score. I really enjoyed it, that’s the truth. I had 70 minutes of a team giving everything, I don’t think we’ve had that many attempts in the Championship this season. “It’s a rude awakening, last year we would’ve won that 4-2.”St. Thomas police investigating retail theftAmid some Republican Party infighting, one GOP congressman is seeking to unite his caucus behind House Speaker Mike Johnson ahead of a pivotal vote that will decide whether he retains the gavel in 2025. Appearing Sunday on ABC's "This Week," Rep. Mike Lawler of New York said Republicans are "playing with fire" if they are considering replacing Johnson as speaker of the House, pointing to the chaotic removal of former House Speaker Kevin McCarthy last year. RELATED STORY | Trump endorses Speaker Johnson to retain House gavel in 2025 "The fact is that these folks are playing with fire," Lawler said. "And if they think they're somehow going to get a more conservative Speaker, they're kidding themselves." "We can't get anything done unless we have a Speaker — including certifying President Trump's election on January 6th," Lawler added. "So, to waste time over a nonsensical, intramural food fight is a joke." RELATED STORY | Upcoming Congressional committees take shape on Capitol Hill Johnson won a unanimous voice vote during nominations for House GOP Conference leadership in November, but now faces a formal vote in the House when the next Congress begins in January. He will need to secure 218 votes, which means he can't afford many defections from Republicans, who are currently projected to hold a slim majority with 220 seats.
Unrivaled signs LSU star Flau'jae Johnson to NIL deal
The chaos and frustrations of the launch day highlighted the importance of thorough stress-testing and capacity planning for such high-profile events. While the overwhelming response from users was a testament to the website's popularity, it also served as a stark reminder of the critical role that robust server infrastructure plays in ensuring a smooth online experience.In the end, it's not just about winning matches and advancing in the competition. It's about upholding the tradition and honor of wearing the iconic red and black colors of AC Milan. It's about representing the millions of passionate fans around the world who live and breathe for their beloved club. And it's about showcasing the beauty and magic of the beautiful game to a global audience.
The Uruguayan striker also pointed out the difficult circumstances Emery faced during his time at Arsenal, including injuries to key players and the departure of star player, Aaron Ramsey. "It's never easy to deal with so many challenges at once, but Unai did his best to navigate through a tough period for the club," Suarez added.Trump’s tariffs in his first term did little to alter the economy, but this time could be differentPedro escaped punishment after swinging an arm at Bees substitute substitute Yehor Yarmoliuk without making contact. VAR reviewed the second-half incident but deemed there was no violent conduct. Frank and Brighton head coach Fabian Hurzeler disagreed about the decision. “As I understand the rules, you can’t swing your arm to try to hit someone,” said Frank. “If you hit them or not, it’s a red, that’s the way I understand the rules.” Frank spoke to the match officials, including referee Andy Madley, about the flashpoint at full-time. “They haven’t seen the situation yet, not on TV afterwards,” said Frank. “To be fair to him, I think the angle can be tricky so that’s why you’ve got VAR.” Asked about Frank’s assessment, Hurzeler replied: “Interesting opinion. I see it completely different. “For me, it’s not a red card. He tried to get free from a person.” Brighton were booed off after their winless run was stretched to six top-flight games. Albion dominated for large periods and hit the woodwork inside four minutes through Julio Enciso. Bees goalkeeper Mark Flekken made some important saves before being forced off injured in the 36th minute, albeit his replacement Hakon Valdimarsson was rarely tested on his Premier League debut. The Seagulls remain 10th ahead of Monday’s trip to Aston Villa, with Brentford a position and two points below moving towards their New Year’s Day showdown with Arsenal. Hurzeler thought the jeers at full-time were unfair. “The team doesn’t deserve that because in all the games we had in the last weeks they were all good, they were all intense, they were all where we thought we deserved more” said the German, whose team have lost to Fulham and Crystal Palace and drawn with Southampton, Leicester and West Ham in recent matches. “We try to work hard to satisfy our supporters, we try to give them what they deserve, we try to make them proud. “But the Premier League is tough. We know there will be (tough) periods we have to go through, especially with this young squad. “We try to stick together, find the positive and keep on going.” Brentford, who remain without a top-flight away win this term, had an early Yoane Wissa finish ruled out for offside following VAR intervention but barely threatened, despite an improved second-half showing. Frank, who is awaiting news on Flekken and defender Ben Mee, who also left the field injured, said: “I thought it was a fair point. “Brighton were better in the first half, no big, clearcut chances, and I thought we were better second half. “Overall, I’m happy with the performance, especially the way we defended. “We haven’t had too many clean sheets this season, so in that context I thought it was very impressive against a good Brighton team. “We know we have a lot of players out – we get two more injuries during the game. “The way the players showed their mentality and character and dug in was hugely impressive.”
In conclusion, Natural Beauty Group's participation in the Visionary Data Intelligence Decision Summit was a testament to their dedication to innovation, customer-centricity, and sustainability. By sharing their insights and best practices in omnichannel digital innovation and AI implementation, they have inspired and empowered other industry players to embrace the transformative potential of data intelligence and technology. As we navigate through the ever-evolving digital landscape, Natural Beauty Group stands as a beacon of excellence, driving the beauty industry towards a more data-driven and customer-focused future.WEST PALM BEACH, Fla. — An online spat between factions of Donald Trump's supporters over immigration and the tech industry has thrown internal divisions in his political movement into public display, previewing the fissures and contradictory views his coalition could bring to the White House. The rift laid bare the tensions between the newest flank of Trump's movement — wealthy members of the tech world including billionaire Elon Musk and fellow entrepreneur Vivek Ramaswamy and their call for more highly skilled workers in their industry — and people in Trump's Make America Great Again base who championed his hardline immigration policies. The debate touched off this week when Laura Loomer , a right-wing provocateur with a history of racist and conspiratorial comments, criticized Trump’s selection of Sriram Krishnan as an adviser on artificial intelligence policy in his coming administration. Krishnan favors the ability to bring more skilled immigrants into the U.S. Loomer declared the stance to be “not America First policy” and said the tech executives who have aligned themselves with Trump were doing so to enrich themselves. Much of the debate played out on the social media network X, which Musk owns. Loomer's comments sparked a back-and-forth with venture capitalist and former PayPal executive David Sacks , whom Trump has tapped to be the “White House A.I. & Crypto Czar." Musk and Ramaswamy, whom Trump has tasked with finding ways to cut the federal government , weighed in, defending the tech industry's need to bring in foreign workers. It bloomed into a larger debate with more figures from the hard-right weighing in about the need to hire U.S. workers, whether values in American culture can produce the best engineers, free speech on the internet, the newfound influence tech figures have in Trump's world and what his political movement stands for. Trump has not yet weighed in on the rift. His presidential transition team did not respond to questions about positions on visas for highly skilled workers or the debate between his supporters online. Instead, his team instead sent a link to a post on X by longtime adviser and immigration hard-liner Stephen Miller that was a transcript of a speech Trump gave in 2020 at Mount Rushmore in which he praised figures and moments from American history. Musk, the world's richest man who has grown remarkably close to the president-elect , was a central figure in the debate, not only for his stature in Trump's movement but his stance on the tech industry's hiring of foreign workers. Technology companies say H-1B visas for skilled workers, used by software engineers and others in the tech industry, are critical for hard-to-fill positions. But critics have said they undercut U.S. citizens who could take those jobs. Some on the right have called for the program to be eliminated, not expanded. Born in South Africa, Musk was once on an a H-1B visa himself and defended the industry's need to bring in foreign workers. “There is a permanent shortage of excellent engineering talent," he said in a post. “It is the fundamental limiting factor in Silicon Valley.” Trump's own positions over the years have reflected the divide in his movement. His tough immigration policies, including his pledge for a mass deportation, were central to his winning presidential campaign. He has focused on immigrants who come into the U.S. illegally but he has also sought curbs on legal immigration , including family-based visas. As a presidential candidate in 2016, Trump called the H-1B visa program “very bad” and “unfair” for U.S. workers. After he became president, Trump in 2017 issued a “Buy American and Hire American” executive order , which directed Cabinet members to suggest changes to ensure H-1B visas were awarded to the highest-paid or most-skilled applicants to protect American workers. Trump's businesses, however, have hired foreign workers, including waiters and cooks at his Mar-a-Lago club , and his social media company behind his Truth Social app has used the the H-1B program for highly skilled workers. During his 2024 campaign for president, as he made immigration his signature issue, Trump said immigrants in the country illegally are “poisoning the blood of our country" and promised to carry out the largest deportation operation in U.S. history. But in a sharp departure from his usual alarmist message around immigration generally, Trump told a podcast this year that he wants to give automatic green cards to foreign students who graduate from U.S. colleges. “I think you should get automatically, as part of your diploma, a green card to be able to stay in this country," he told the “All-In" podcast with people from the venture capital and technology world. Those comments came on the cusp of Trump's budding alliance with tech industry figures, but he did not make the idea a regular part of his campaign message or detail any plans to pursue such changes.
For many across the Middle East, the came as a relief: the first major sign of progress in the region since war began more than a year ago. But for Palestinians in Gaza and families of hostages held in the territory, the only to inaugurate a newer, grimmer period of the conflict there. For them, it marked yet another missed opportunity to end fighting that has stretched on for nearly 14 months. Palestinians had hoped that any ceasefire deal with Hezbollah would include a truce in Gaza as well. The families of people kidnapped when in October 2023, meanwhile, wanted part of the agreement to include returning their loved ones. Instead, the ceasefire was . “We feel this is a missed opportunity to tie in the hostages in this agreement that was signed today,” said Ruby Chen, whose son, Itay Chen, was taken hostage from an Israeli military base and has been declared dead. As much as they were intertwined, the two wars have been very different. In Lebanon, Israel said its aim was to drive Hezbollah back from the countries’ shared border and end the militant group’s barrages into northern Israel. The ceasefire is intended to do that. In Gaza, Israel’s goals . Prime Minister Benjamin Netanyahu has been resolute in insisting that Hamas must be completely destroyed and Israel must retain lasting control over parts of the territory. Months of talks have failed to get Netanyahu to back down from those demands — or to convince Hamas to release hostages under those terms. For Palestinians in Gaza, that means continuing misery under an Israeli campaign that has and driven almost the entire population from their homes. Hundreds of thousands while living in squalid tent cities as the second winter of the war brings cold rains and flooding. ”They agree to a ceasefire in one place and not in the other? Have mercy on the children, the elderly and the women,” said Ahlam Abu Shalabi, living in tent in central Gaza. “Now it is winter, and all the people are drowning.” Palestinians feel resigned to continued war The war between Israel and Hamas began on Oct. 7, 2023, when militants attacked Israel from Gaza, killing around 1,200 people and taking some 250 hostage. Israel’s retaliatory offensive has rained devastation on the Palestinian territory, killing over 44,000 people, according to local health officials. The officials, who do not distinguish between civilians and fighters in their count, say over half of the dead are women and children. Hezbollah began firing into Israel a day after Hamas’ attack in solidarity with the Palestinian militant group. The two sides have exchanged near-daily barrages since. Moving thousands of troops to its northern border, Israel ramped up bombardment of southern Lebanon and launched a ground invasion there two months ago, . Palestinians now fear Israel’s military can return its full focus to Gaza — a point that Netanyahu made as he announced the ceasefire in Lebanon on Tuesday. “The pressure will be more on Gaza,” said Mamdouh Younis, a displaced man in a central Gaza tent camp. Netanyahu, he said, can now exploit the fact that “Gaza has become alone, far from all the arenas that were supporting it, especially the Lebanon front.” Israeli troops are already engaged in , where a two-month offensive has cut off most aid and caused experts to warn . Strikes all over the territory regularly kill dozens. In signing onto the ceasefire deal, Hezbollah reversed its long-held position that it wouldn’t stop its barrages across the border unless Israel ends the war in Gaza. “This could have a psychological impact, as it will further entrench the understanding that Palestinians in Gaza are alone in resisting against their occupiers,” said Tariq Kenney Shawa, a U.S. policy fellow at Al-Shabaka, a Palestinian think tank. Hamas may dig its heels in It also leaves Hamas — its capabilities already severely damaged by Israel’s offensive — to fight alone. Hamas official Osama Hamdan appeared to accept Hezbollah’s new position in an interview Monday. “Any announcement of a ceasefire is welcome. Hezbollah has stood by our people and made significant sacrifices,” Hamdan told the Lebanese broadcaster Al-Mayadeen, which is seen as politically allied with Hezbollah. Khalil Sayegh, a Palestinian analyst, said the ceasefire could make Hamas even less popular in Gaza, by proving the failure of its gambit that its attack on Israel would rally other militant groups to the fight. “It’s a moment where we can see the Hamas messaging become weaker and weaker, as they struggle to justify their strategy to the public,” said Sayegh. U.S. Secretary of State Antony Blinken said Tuesday that the Israel-Hezbollah ceasefire could help force Hamas to the negotiating table because it would show the group that the “cavalry is not on the way.” But Hamas experts predicted that it would only dig in both on the battlefield and in talks. Hamas has insisted it will only release all the hostages in return for a full Israeli withdrawal from Gaza. “I expect Hamas will continue using guerrilla warfare to confront Israeli forces in Gaza as long as they remain,” said Shawa. Hostage families lose hope Dozens of Israelis thronged a major highway in Tel Aviv on Tuesday night, protesting for the return of the hostages as the country waited to hear if a ceasefire in Lebanon had been agreed. Around 100 people taken hostage are still held in Gaza, at least a third of whom are believed to be dead. Most of the other hostages seized by Hamas were released during a ceasefire last year. Ricardo Grichener, the uncle of 23-year-old hostage Omer Wenkert, said the ceasefire with Hezbollah showed how the Israeli government was openly disregarding the hostages. Even though Israel has inflicted greater damage on Hamas in Gaza than on Hezbollah in Lebanon, he said “the decision to postpone a deal in Gaza and release the hostages is not based on the same military success criteria.” The most recent effort to wind down the war stalled in October. U.S. President Joe Biden said Tuesday he would begin a renewed push, but his administration is now in its waning days after the reelection of former President Donald Trump. “This ceasefire doesn’t concern our hostages. I believe that Netanyahu forgot about them, and he just wants to keep fighting in Gaza,” said Ifat Kalderon, clutching a photo of her cousin, Ofer Kalderon, who is a hostage and a father to four. “Ofer yesterday had his 54th birthday. His second birthday in Gaza,” she said. “It’s unbelievable that he’s still there.”
CRANFORD, N.J. , Dec. 27, 2024 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a specialty biopharmaceutical company focused on the development and commercialization of novel targeted oncology therapies, today reported business and financial results for the fiscal full year ended September 30, 2024 . Fiscal Full Year 2024 Business Highlights and Subsequent Developments Financial Highlights "Reflecting on 2024, Citius Oncology has achieved pivotal milestones that underscore our commitment to advancing cancer therapeutics," stated Leonard Mazur , Chairman and CEO of Citius Oncology. "The FDA's approval of LYMPHIR for the treatment of cutaneous T-cell lymphoma marks a significant advancement in providing new options for patients battling this challenging disease. It is the only targeted systemic therapy approved for CTCL patients since 2018 and the only therapy with a mechanism of action that targets the IL-2 receptor. Additionally, the successful merger forming Citius Oncology, now trading on Nasdaq under the ticker CTOR, strengthens our position in the oncology sector. We expect it to facilitate greater access to capital to fund LYMPHIR's launch and the Company's future growth. With a Phase I investigator-initiated clinical trial combining LYMPHIR with pembrolizumab demonstrating promising preliminary results, indicating potential for enhanced treatment efficacy in recurrent solid tumors, and preliminary results expected from a second investigator trial with CAR-T therapies in 2025, we remain excited about the potential of LYMPHIR as a combination immunotherapy." "These accomplishments reflect the dedication of our team and the trust of our investors. As we look ahead, we remain steadfast in our mission to develop innovative therapies that improve the lives of cancer patients worldwide," added Mazur. FULL YEAR 2024 FINANCIAL RESULTS: Research and Development (R&D) Expenses R&D expenses were $4.9 million for the full year ended September 30, 2024 , compared to $4.2 million for the full year ended September 30, 2023 . The increase reflects development activities completed for the resubmission of the Biologics License Application of LYMPHIR in January 2024 , which were associated with the complete response letter remediation. General and Administrative (G&A) Expenses G&A expenses were $8.1 million for the full year ended September 30, 2024 , compared to $5.9 million for the full year ended September 30, 2023 . The increase was primarily due to costs associated with pre-commercial and commercial launch activities of LYMPHIR including market research, marketing, distribution and drug product reimbursement from health plans and payers. Stock-based Compensation Expense For the full year ended September 30, 2024 , stock-based compensation expense was $7.5 million as compared to $2.0 million for the prior year. The primary reason for the $5.5 million increase was due to the amounts being realized over 12 months in the year ended September 30, 2024 , as compared to three months post-plan adoption in the year ended September 30, 2023 . Net loss Net loss was $21.1 million , or ($0.31) per share for the year ended September 30, 2024 , compared to a net loss of $12.7 million , or ($0.19) per share for the year ended September 30, 2023 . The $8.5 million increase in net loss was primarily due to the increase in our operating expenses. About Citius Oncology, Inc. Citius Oncology specialty is a biopharmaceutical company focused on developing and commercializing novel targeted oncology therapies. In August 2024 , its primary asset, LYMPHIR, was approved by the FDA for the treatment of adults with relapsed or refractory CTCL who had had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds $400 million , is growing, and is underserved by existing therapies. Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further support Citius Oncology's competitive positioning. Citius Oncology is a publicly traded subsidiary of Citius Pharmaceuticals. For more information, please visit www.citiusonc.com Forward-Looking Statements This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Oncology. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated, and, unless noted otherwise, that apply to Citius Oncology are: our ability to raise additional money to fund our operations for at least the next 12 months as a going concern; our ability to commercialize LYMPHIR and any of our other product candidates that may be approved by the FDA; the estimated markets for our product candidates and the acceptance thereof by any market; the ability of our product candidates to impact the quality of life of our target patient populations; our dependence on third-party suppliers; our ability to procure cGMP commercial-scale supply; risks related to research using our assets but conducted by third parties; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; government regulation; competition; as well as other risks described in our Securities and Exchange Commission ("SEC") filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our SEC filings which are available on the SEC's website at www.sec.gov , including in Citius Oncology's Annual Report on Form 10-K for the year ended September 30, 2024 , filed with the SEC on December 27, 2024 , as updated by our subsequent filings with the SEC. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. Investor Contact: Ilanit Allen ir@citiuspharma.com 908-967-6677 x113 Media Contact: STiR-communications Greg Salsburg Greg@STiR-communications.com -- Financial Tables Follow – CITIUS ONCOLOGY, INC. CONSOLIDATED BALANCE SHEETS SEPTEMBER 30, 2024 AND 2023 2024 2023 Current Assets: Cash and cash equivalents $ 112 $ — Inventory 8,268,766 — Prepaid expenses 2,700,000 7,734,895 Total Current Assets 10,968,878 7,734,895 Other Assets: In-process research and development 73,400,000 40,000,000 Total Other Assets 73,400,000 40,000,000 Total Assets $ 84,368,878 $ 47,734,895 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Accounts payable $ 3,711,622 $ 1,289,045 License payable 28,400,000 — Accrued expenses — 259,071 Due to related party 588,806 19,499,119 Total Current Liabilities 32,700,429 21,047,235 Deferred tax liability 1,728,000 1,152,000 Note payable to related party 3,800,111 — Total Liabilities 38,228,540 22,199,235 Stockholders' Equity: Preferred stock - $0.0001 par value; 10,000,000 shares authorized: no shares issued and outstanding — — Common stock - $0.0001 par value; 100,000,000; 71,552,402 and 67,500,000 shares issued and outstanding at September 30, 2024 and 2023, respectively 7,155 6,750 Additional paid-in capital 85,411,771 43,658,750 Accumulated deficit (39,278,587) (18,129,840) Total Stockholders' Equity 46,140,339 25,535,660 Total Liabilities and Stockholders' Equity $ 84,368,878 $ 47,734,895 CITIUS ONCOLOGY, INC. CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE YEARS ENDED SEPTEMBER 30, 2024 AND 2023 2024 2023 Revenues $ — $ — Operating Expenses: Research and development 4,925,001 4,240,451 General and administrative 8,148,929 5,915,290 Stock-based compensation – general and administrative 7,498,817 1,965,500 Total Operating Expenses 20,572,747 12,121,241 Loss before Income Taxes (20,572,747) (12,121,241) Income tax expense 576,000 576,000 Net Loss $ (21,148,747) $ (12,697,241) Net Loss Per Share – Basic and Diluted $ (0.31) $ (0.19) Weighted Average Common Shares Outstanding – Basic and Diluted 68,053,607 67,500,000 CITIUS ONCOLOGY, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE YEARS ENDED SEPTEMBER 30, 2024 AND 2023 2024 2023 Cash Flows From Operating Activities: Net loss $ (21,148,747) $ (12,697,241) Adjustments to reconcile net loss to net cash provided by operating activities: Stock-based compensation expense 7,498,817 1,965,500 Deferred income tax expense 576,000 576,000 Changes in operating assets and liabilities: Inventory (2,133,871) - Prepaid expenses (1,100,000) (5,044,713) Accounts payable 2,422,577 1,196,734 Accrued expenses (259,071) (801,754) Due to related party 14,270,648 14,805,474 Net Cash Provided By Operating Activities 126,353 - Cash Flows From Investing Activities: License payment (5,000,000) - Net Cash Used In Investing Activities (5,000,000) - Cash Flows From Financing Activities: Cash contributed by parent 3,827,944 - Merger, net (2,754,296) - Proceeds from issuance of note payable to related party 3,800,111 - Net Cash Provided By Financing Activities 4,873,759 - Net Change in Cash and Cash Equivalents 112 - Cash and Cash Equivalents – Beginning of Year - - Cash and Cash Equivalents – End of Year $ 112 $ - Supplemental Disclosures of Cash Flow Information and Non-cash Activities: IPR&D Milestones included in License Payable $ 28,400,000 $As the film gears up for its highly-anticipated release on New Year's Eve, audiences can look forward to a rollicking comedy that celebrates the joy of laughter and the power of friendship. "Moonlight Bang!" is not just a film, but an experience that will leave a lasting impression on viewers, reminding them of the magic of cinema and the universal language of humor.Enbridge Inc. stock rises Wednesday, still underperforms market
Former US president Jimmy Carter dead at 100
In addition to the operational violations, the investigation also found discrepancies in the financial management of the kindergarten. Reports indicate that there were irregularities in the handling of tuition fees and other financial transactions, raising concerns about transparency and accountability within the institution.
